Among these two anti‐TNF agents, adalimumab may have fewer adverse effects (odds ratio [OR] 0.62 [95% confidence intervals [CI] 0.42–0.91]) [42], mostly related to infections, musculoskeletal disorders, and gastrointestinal disorders [43]. Here, TNF is linked to infection.